<DOC>
	<DOCNO>NCT01577069</DOCNO>
	<brief_summary>The purpose study 1- detect quantify HCV-PI resistant mutant ultra-deep pyrosequencing ( UDPS ) technology , 2 - detect SNPs P-glyocoprotein CYP3A gene , HCV mono-infected patient under/after Telaprevir treatment .</brief_summary>
	<brief_title>Predictive Factors Treatment Failure Hepatitis C Virus ( HCV ) Infected Patients Treated With Telaprevir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>HCV monoinfected subject Age &gt; 18 year HBV coinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Direct Antiviral agent ( DAA )</keyword>
	<keyword>Ultra-deep pyrosequencing</keyword>
	<keyword>Single polynucleotide polymorphism</keyword>
	<keyword>Treatment-resistant mutant</keyword>
	<keyword>Hepatitis C Virus Protease Inhibitor</keyword>
</DOC>